Targeting vimentin for cancer therapy

Study vimentin using a flexible product offering tailored to your research requirements.

A major contributor to metastasis is the process of epithelial to mesenchymal transition (EMT). Vimentin is a canonical marker of the EMT process and a clinical marker of metastasis. It’s overexpression in epithelial cancers including lung, prostate and breast makes it an attractive target for cancer therapy1,2.

How we can help you

By providing a flexible and tailored approach via custom services and a secure source of research tools, we can help you achieve your vimentin research goals.

Vimentin recombinant rabbit monoclonal antibody (ab92547) staining in human ovarian cancer tissue using immunohistochemistry (formaldehyde-fixed, paraffin-embedded sections). Image courtesy of Mr Carl Hobbs, Kings College London.


Flexible antibody formulations. Antibodies against vimentin and EMT-related proteins are available in PBS-only formulations and conjugated to fluorophores and enzymes. See all options for anti-vimentn recombinant rabbit monoclonal antibody (ab92547).

Comprehensive range of vimentin and EMT-related products. Antibodies and small molecules specific to study vimentin from all angles and target all stages of EMT.

Custom antibody services. Generate rabbit monoclonal antibodies against your target of interest using our patented RabMAb® technology. Learn more.

Large amounts and consistency of supply. Secure the supply of your favorite products.

Custom miRNA profiling. Profile miRNAs that regulate cancer metastasis with our Firefly particle technology. We offer cutom miRNA panel design to provide you with an assay tailored to your needs.

If you don’t find what you need, please contact us. Our expert customer services team will be happy to help you with your specific request.


References

  • 1. Kidd, M. E., Shumaker, D. K. & Ridge, K. M. The Role of Vimentin Intermediate Filaments in the Progression of Lung Cancer. Am. J. Respir. Cell Mol. Biol. 130827094923003 (2013). doi:10.1165/rcmb.2013-0314TR
  • 2. Satelli, A. & Li, S. Vimentin in cancer and its potential as a molecular target for cancer therapy. Cell. Mol. Life Sci. 68, 3033–3046 (2011).
Sign up